Is Avonib included in medical insurance?

Avosidenib is not yet included in medical insurance. Ivosidenib (ivosidenib) is a targeted therapy drug that has important clinical significance for acute myeloid leukemia (AML) caused by specific gene mutations.

Although ivonib is already on the market in China and is approved for the treatment of adult patients with relapsed or refractory AML carrying IDH1 mutations, it is currently not included in the medical insurance system. This means that patients are required to pay the full amount out-of-pocket when purchasing.

The National Medical Insurance Administration is responsible for updating the medical insurance catalog, and drugs need to go through a series of strict evaluation and decision-making procedures before they can be included in medical insurance. This includes assessing the drug's clinical value, safety, effectiveness and conducting economic evaluations. Therefore, if Ivonib is to be included in medical insurance, it still needs to go through these procedures.

For patients who need to use ivonib for treatment, although the drug has not yet been included in medical insurance, they can still purchase this drug through hospital pharmacies or formal and legal overseas channels. Of course, this requires the patient to bear all costs.

According to the latest drug information, the price of ivonib in China is relatively high, about 10yuan, which is a considerable burden for many patients. Therefore, patients and families need to fully consider cost when making treatment decisions.

Although ivonib is not currently included in medical insurance, whether it may be included in the future is a question worthy of attention. Patients and family members can pay attention to updates to the medical insurance catalog and changes in related policies to learn in a timely manner whether there are new ways to obtain support for drug costs.